文章：

阿特珠单抗与贝伐珠单抗联合疗法在晚期肝细胞癌治疗中的应用

Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer

原文发布日期：30 December 2023

DOI: 10.3390/cancers16010197

类型: Article

开放获取: 是

英文摘要：

Liver cancer, particularly hepatocellular carcinoma, is a global concern. This study focuses on the evaluation of Atezolizumab and Bevacizumab combination therapy as a promising alternative in the treatment of advanced hepatocellular carcinoma. The objectives of this systematic review include evaluating the efficacy of Atezolizumab and Bevacizumab combination therapy compared to conventional therapies with Sorafenib and other conventional therapies, analyzing the associated adverse effects, and exploring prognostic factors in the setting of advanced hepatocellular carcinoma. A systematic literature review was carried out using the PubMed and Web of Science databases. Fifteen related articles were included and evaluated according to their level of evidence and recommendation. Results: The combination therapy of Atezolizumab and Bevacizumab, along with Sorafenib, showed positive results in the treatment of patients with advanced hepatocellular carcinoma. Significant adverse effects were identified, such as gastrointestinal bleeding, arterial hypertension, and proteinuria, which require careful attention. In addition, prognostic factors, such as transforming growth factor beta (TGF-β), alpha-fetoprotein (AFP), and vascular invasion, were highlighted as key indicators of hepatocellular carcinoma progression. Conclusions: The combination of Atezolizumab and Bevacizumab is shown to be effective in the treatment of advanced hepatocellular carcinoma, although it is essential to take into consideration the associated adverse effects. The prognostic factors identified may provide valuable information for the clinical management of this disease. This study provides a comprehensive overview of a promising emerging therapy for liver cancer.

摘要翻译： 

肝癌，尤其是肝细胞癌，是全球关注的重大健康问题。本研究旨在评估阿特珠单抗与贝伐珠单抗联合疗法作为晚期肝细胞癌治疗中一种有前景的替代方案。本系统综述的目标包括：评估阿特珠单抗与贝伐珠单抗联合疗法相较于索拉非尼及其他常规疗法的疗效，分析相关不良反应，并探讨晚期肝细胞癌的预后因素。研究通过PubMed和Web of Science数据库进行了系统性文献检索，共纳入15篇相关文章，并根据其证据等级和推荐强度进行了评估。结果显示：阿特珠单抗与贝伐珠单抗联合疗法以及索拉非尼在晚期肝细胞癌患者的治疗中均显示出积极效果。研究同时识别出需密切关注的重要不良反应，如胃肠道出血、动脉性高血压和蛋白尿。此外，转化生长因子-β（TGF-β）、甲胎蛋白（AFP）及血管侵犯等预后因素被强调为肝细胞癌进展的关键指标。结论：阿特珠单抗与贝伐珠单抗联合疗法在晚期肝细胞癌治疗中显示有效，但必须充分考虑其相关不良反应。所识别的预后因素可能为该疾病的临床管理提供有价值的信息。本研究为这一前景广阔的新兴肝癌疗法提供了全面概述。

原文链接：

Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer